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Abstract 
Objective: We estimated the cost consequence of the Italian National Health System (NHS) investment in Direct-acting 
Antiviral drugs (DAA) according to hepatitis C virus (HCV) treatment access policies in Italy.  
Methods: A multistate 20-year time horizon Markov model of HCV liver disease progression was developed. Fibrosis 
stage, age and genotype distributions were derived from the Italian Platform for the Study of Viral Hepatitis Therapies 
(PITER) cohort. The treatment efficacy, disease progression probabilities and direct costs in each health state were 
obtained from the literature. The break-even point in time (BPT) was defined as the period of time required for the 
cumulative costs saved to recover the Italian NHS investment in DAA treatment. Three different PITER enrolment 
periods, which covered the full DAA access evolution in Italy, were considered.  
Results: The disease stages of 2657 patients who consecutively underwent DAA therapy from January 2015 to 
December 2017 at 30 PITER clinical centres were standardized for 1,000 patients. The investment in DAAs was 
considered to equal €25 million, €15 million, and €9 million in 2015, 2016 and 2017, respectively. For patients treated 
in 2015, the BPT was not achieved due to the disease severity of the treated patients and high DAA prices. For 2016 
and 2017, the estimated BPTs were 6.6 and 6.2 years, respectively. The total cost savings after 20 years were €50.13 
and €55.50 million for 1,000 patients treated in 2016 and 2017, respectively.  
Conclusions: This study may be a useful tool for public decision makers to understand how HCV clinical and 
epidemiological profiles influence the economic burden of HCV.  
 
Key points for decision makers 
• Following the Direct-acting Antiviral drugs (DAA) treatment in patients who had severe liver disease, treated 
in 2015, only a significant health benefit, with no break-even point to recover the investment in DAA across 20 
years was estimated. 
• The time required for the cumulative costs saved to recover the initial Italian NHS investment in DAA 
treatment was estimated to be 6.6 years and 6.2 years for patients treated in 2016 and 2017 respectively. 
• The overall results of this cost-consequence analysis, based on real-life HCV treatment data from a 
representative sample of Italian patients in care, confirm an overall health benefit of DAA anti-HCV treatment. 
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1. Introduction 
 Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide [1]. According 
to recent estimates, more than 71 million people around the world are infected with HCV [2, 3]. Despite declining HCV 
infection rates, the burden of HCV is still high [4]. The effects of therapies on morbidity and mortality and as well as 
their economic consequences vary significantly between countries due to the different epidemiological profiles of HCV 
infection. Regarding the epidemiology of HCV, past incidence of infection was assumed to follow a logistic function 
until infection rates peaked in 1989 in different countries. However, in Italy, a more intense epidemic wave occurred 
from the 1950s to the 1960s via iatrogenic transmission due to the use of unsterilized materials [5, 6]. For this reason, a 
longer exposure time suggests a potential higher prevalence of advanced liver disease stages among individuals with 
chronic HCV infection in Italy compared to those in countries in which the epidemic waves occurred later. In fact, Italy 
has the highest prevalence of HCV in Europe and the highest death rate due to hepatocellular carcinoma (HCC) and 
liver cirrhosis [7]. Each year, more than 20,000 chronic liver disease-complicated deaths are reported, and in more than 
65% of them, HCV is the main aetiological factor. HCC is the 5th leading cause of death from cancer in Italy [8]. 
Genotype 1 occurs most frequently in Italian patients with chronic HCV infection (and in more than 50% of infected 
people in the general population), followed by genotype 2c. Both genotypes are related to the nosocomial transmission 
mode of HCV infection, the principal route of HCV transmission in Italy [9, 10]. Considering this transmission 
peculiarity, Italy represents an interesting epidemiological context in that severe stages of liver disease and the 
corresponding economic burden in Italy are higher than those in countries with different epidemiology of infection. 
During the past four years, the AIFA policy perspective has radically changed. In 2015, the AIFA decided 
reimbursement policies based on the prioritization of symptomatic individuals with moderate-to-severe liver fibrosis 
and a few other patients categories. Since 2017, the AIFA’s access to therapy has become universal independent of the 
liver fibrosis stage, and treatment has become available for all chronically infected HCV patients [11]. 
 From the economic perspective, cost-effectiveness and cost-sustainability have been studied in Italy [12-15], 
and the data demonstrated the economic efficiency and sustainability of the Direct-Acting Antiviral (DAA) therapy 
investment. Apart from these studies, no specific analysis has estimated the economic consequences of the Italian 
National Health System (NHS) investment and access to treatment. In 2014, an initial study proposed by Mennini et al. 
[16] attempted to provide decision makers with fundamental information for reflection and discussion and allow them 
to plan the implementation of rational and economically sustainable actions with the aim of controlling and eradicating 
the infection. In that study, the authors calculated the economic effect in terms of the direct and indirect costs 
(excluding drug costs) of DAA treatment in Italy, estimating a cost savings between €192 and €198 million depending 
on the access scenario [16]. 
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 The high number of DAA treated patients has resulted in an increased investment associated with drug 
acquisition costs from the NHS and, consequentially, increased healthcare cost savings due to the avoidance of diseases 
related to HCV. However, whether the two costs offset each other over time remains in question. 
 The aim of this work was to estimate the cost consequence of the NHS investment in DAA-based anti-HCV 
treatment in Italy according to the fibrosis stage and access to DAA treatment information based on real-life data from a 
representative sample of patients treated in Italy. The final goal was to estimate the amount of time required for the 
initial NHS investment in DAA treatment to achieve cumulative cost savings due to HCV-related disease avoidance. 
2. Methods 
 A specific Markov model was designed to estimate the clinical and economic consequences of HCV treatment 
in the Italian setting. [17]. The model simulated the cost sustained by the Italian NHS for DAA treatment of HCV 
chronically infected patients during the years 2015, 2016 and 2017. The  liver disease progression of treated patients 
was evaluated through the model over 20 years’ time horizon. Direct medical costs were estimated according to the 
fibrosis and HCV genotype stratification of the HCV chronically infected patients, consecutively treated in the PITER 
(Piattaforma Italiana per lo studio della Terapia delle Epatiti ViRali) real life cohort [17].  
 
 
2.1 Model structure 
 Starting from the mortality-morbidity multistate model recently developed by Marcellusi et al. in 2016 [12], a 
new Markovian process was implemented. It included 13 disease states [fibrosis stages from F0 to F4, decompensated 
cirrhosis (DC), hepatocellular carcinoma (HCC), first-year transplant and following years transplant, sustained virologic 
response (SVR) from F0 to F3, SVR from irreversible liver damage (ILD), HCV-related death, and death from other 
causes] and 41 transition probabilities (Figure 1). The SVR from ILD states represent patients treated in the states F4, 
DC and HCC that achieve an SVR after one year of treatment. Patients can be entered into the Markov process from 
different fibrosis stages (F0-F3), compensated and DC states and the HCC state.  The proportions of disease stages were 
defined   according to the PITER  distribution of the fibrosis stage of  treated patients for each period considered in the 
analysis. An NHS perspective was considered (only direct medical costs). Simulations for a 20-year period for each of 
the three treatment years, 2015, 2016 and 2017, were performed.  
 
 
2.2 Epidemiological and clinical parameters 
6 
 
 Data stratifications for the disease states, genotypes and ages of DAA-treated patients were retrieved from the 
PITER database. PITER is a structured network that benefits from an integrated collaboration involving Italy's National 
Institute of Public Health (Istituto Superiore di Sanità), the Italian Society for the Study of the Liver (AISF), the Italian 
Society for Infectious Diseases (SIMIT) and their affiliated clinical centres. The PITER database comprises an ongoing 
cohort of consecutively enrolled patients from hospital centres across Italy linked to care for chronic HCV infection 
who are not on an HCV treatment regimen at the time of enrolment. The cohort can be reasonably considered to be a 
representative sample of patients in care with no treatment access restrictions on the basis of sociodemographic and 
healthcare system reimbursement criteria [17]. 
 Treatment initiations occurring among enrolled patients covered the full evolution of DAA access in Italy since 
2015. The first round of enrolment began in May 2014 and lasted 6 months, and three rounds of enrolment were 
conducted through December 2017. Treated patients were grouped into 3 time periods for analysis: 2015 (patients 
treated from January-December 2015), 2016 (patients treated from January–December 2016) and 2017 (patients treated 
from January–December 2017). 
 The three-time period analysis represented the AIFA reimbursement policies of prioritization for symptomatic 
individuals with moderate-to-severe liver fibrosis and a few other categories of patients until the year 2016. In 2017, the 
AIFA expanded the access to treatment to all patients with no fibrosis stage or other restrictions [11].  
2.3 Transition probabilities 
 Progression of HCV liver disease was considered to be an increase in the severity of liver fibrosis (from F0 to 
F4 according to the Metavir classification) or progression to ILD stages. The probabilities of the various stages of 
progression are based on the literature review (Table 1). Throughout annual cycles, patients can remain in their current 
stage or progress to a worse disease state coherently with the natural history of the disease. This progression can be 
stopped or slowed down by treatment. The DAA efficacy is expressed in terms of probability to reach an SVR state. If 
patients are cured in stages F0-F3 (they move to the SVR state), the model assumes that liver damage is reversed. 
Patients achieving an SVR in stages F4, DC and HCC are no longer infectious, but they may incur additional liver 
damage (F4 and DC could progress to HCC) or need a liver transplant (LT). The probabilities of moving from SVR-
irreversible liver damage to HCC or LT are weighted for the percentages of patients with compensated cirrhosis, DC 
and HCC. Patients can die due to HCV-related diseases from only the states DC, HCC, LT (procedure) and LT 
(following years). All probabilities are adjusted for competing probabilities of death from other causes [18].  
 The efficacy parameters of interferon (IFN)-free HCV regimens of second-generation DAAs are stratified by 
the presence or absence of cirrhosis (Table 1). Three different periods, which covered the full evolution of different 
DAA accesses in Italy since 2015, were considered. The SVR of each period was estimated in accordance with the 
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availability of DAAs in the Italian context (Appendix). The SVR rate of each treatment was derived from the literature 
and used to estimate the mean rates of SVR according to the HCV RNA genotype and fibrosis stage weighted for real-
life PITER cohort characteristics. For the F0, F1, F2, F3, F4 and DC states, the probabilities of achieving SVR, disease 
progression and HCV-related death were estimated. For the HCC state, the probability of death due to HCV and the 
probability of transplant were assumed to be independent. All the parameters of base-case analysis were discussed and 
validated by the clinical expert involved in this study and by all the co-authors. 
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2.4 Economic parameters 
 The yearly direct healthcare costs were derived from the literature and considered aggregate costs for the 
management of HCV-related diseases (specialist visits, analyses and check-ups), pharmacological therapies and 
hospitalization costs. The averages costs and ranges (MIN–MAX), available from national literature, are reported in 
Table 1.  
 The average treatment cost per DAA was derived from assumptions made from the literature [19] and added to 
the average cost of the patient’s management. Costs are expressed in euros at the 2017 price level. 
2.5 Economic analysis 
 The outcomes of the model are expressed in terms of HCV-related diseases (DC and HCC), transplant and 
HCV-related death avoidance. Costs were discounted at an annual rate of 3% according to Italian AIES guidelines [20]. 
The economic analysis was performed by standardizing 1,000 patients stratified by fibrosis stage, age and genotype as 
reported in the treated PITER cohort in the three time periods considered.  
 One of the main model outputs was the break-even point in time (BPT), which was an evaluation of the time 
required to incur hepatitis C treatment cost savings. This index was derived from the financial discounted payback 
period, a method that estimates the point in time at which the cumulative, discounted positive cash flows offset the 
initial capital investment [21]. From our perspective, the BPT was defined as the period of time required for the 
cumulative, discounted value of costs saved to recover the initial NHS investment in DAA treatment, which indicates 
how long it takes to break even. The annual costs saved were calculated as the cost difference, including the average 
cost of patient management during the natural history of the disease minus the real-world treatment estimates for each 
period of the analysis. 
 If 𝑖𝑖 = {2015; 2016; 2017} is the period of analysis, t = 0, 1, … 20 is the cycles used in the Markov-model 
simulation, 𝐶𝐶𝐶𝐶𝑡𝑡 is the cash flow in period t (avoided costs due to HCV-related disease reduction), 𝐼𝐼𝑡𝑡 is the initial 
investment in period t for DAA acquisition and r is the discount rate, then the BPT can be defined as follows: 
BPT𝑖𝑖 = min(𝑥𝑥) :�� 𝐶𝐶𝐶𝐶𝑡𝑡𝑖𝑖 (1 + 𝑟𝑟)𝑡𝑡 − 𝐼𝐼𝑡𝑡𝑖𝑖  (1 + 𝑟𝑟)𝑡𝑡�𝑥𝑥
𝑡𝑡=0
≅ 0 
2.6 Sensitivity analysis 
 To estimate the uncertainty of the economic results, probabilistic sensitivity analysis (PSA) and deterministic 
sensitivity analysis (DSA) were performed. 
 For PSA, the probabilistic distribution choice was made by applying what is generally reported for the 
development of economic evaluation models, distinguishing between costs (gamma distribution) and epidemiological 
parameters (beta distribution) and considering the range available from the literature (Table 1) [22]. Furthermore, 5000 
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Monte Carlo simulations were performed to provide 95% confidence intervals (95% CIs) for the primary economic 
results (case and cost reduction at 20 years, BPT and case reduction at the BPT).  
 To highlight the effects of the main model parameters, DSA was conducted via a one-way deterministic 
analysis in which the parameters were changed by arbitrary constant variation:  
• Transition probabilities (-20% to +20%) 
• Treatment costs (-20% to + 20%) 
• Healthcare medical costs (-20% to +20%) 
• % F3, F4, DC and HCC (-20% to +20%) 
• Transplant probability for SVR (0 to +50%) 
• SVR (minimum from the literature to 1) 
 Finally, due to the heterogeneity of different transition probabilities applied in the literature, we performed a 
specific DSA considering the HCV disease progressions estimated from two different Italian studies [4, 23] and from a 
US model that performed a similar analysis (expressed as return to cost-effectiveness) [26]. One-way DSA is 
represented by a tornado diagram, and the specific-transition-probability DSA is presented as the BPT evolution for 
each year.  
Table 1 – Transition probabilities and efficacy of treatments and costs. 
Annual probability of disease progression Base-case Min Max Source 
F0 to F1 0.117 0, 09 0.140 [27] 
F1 to F2 0.085 0.070 0.102 [27] 
F2 to F3 0.120 0.100 0.144 [27] 
F3 to F4 0.100 0.080 0.120 [28] 
F4 to Decompensated Cirrhosis (DC) 0.030 0.020 0.036 [28] 
F4 to HCC 0.050 0.040 0.060 [28] 
Decompensated Cirrhosis to HCC 0.100 0.080 0.120 [28] 
Decompensated Cirrhosis to Transplant 0.110 0.090 0.132 [28] 
HCC to Transplant 0.200 0.160 0.240 [29] 
SVR to HCCa 0.008 0.007 0.009 Assumption from [30] 
SVR to Transplanta 0.016 0.011 0.020 Assumption from [30] 
Annual probability of progressing to death Base-case Min Max Source 
Decompensated Cirrhosis to Death (liver-related) 0.090 0.070 0.108 [30] 
HCC to Death (liver-related) 0.430 0.340 0.516 [29] 
Transplant (procedure) to Death (liver-related) 0.150 0.120 0.180 [29] 
Transplant (following years) to Death (liver-related) 0.057 0.050 0.068 [29] 
Death from all other causes 0.074 0.070 0.108 [18] 
Efficacy of treatments - 2015 Base-case Min Max Source 
F0-F3 to SVR (Genotype 1) 0.879 0.643 0.97 Appendix [25, 31]c 
F4-DC to SVR (Genotype 1) 0.834 0.643 0.954 Appendix [25, 31]c 
F0-F3 to SVR (Genotype 2) 0.742 0.500 0.984 [25, 31]c 
F4-DC to SVR (Genotype 2) 0.742 0.500 0.984 Assumed equal to F0-F3 
F0-F3 to SVR (Genotype 3) 0.758 0.606 0.910 [25, 31]c 
F4-DC to SVR (Genotype 3) 0.758 0.606 0.910 Assumed equal to F0-F3 
F0-F3 to SVR (Genotype 4 and more) 0.525 0.000 0.950 [25, 31]c 
F4-DC to SVR (Genotype 4 and more) 0.525 0.000 0.950 Assumed equal to F0-F3 
Efficacy of treatments - 2016 Base-case Min Max Source 
F0-F3 to SVR (Genotype 1) 0.983 0.963 1.000 Appendix [25]c 
F4-DC to SVR (Genotype 1) 0.928 0.760 1.000 Appendix [25]c 
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F0-F3 to SVR (Genotype 2) 0.960 0.920 1.000 Appendix [25]c 
F4-DC to SVR (Genotype 2) 0.952 0.710 0.975 Appendix [25]c 
F0-F3 to SVR (Genotype 3) 0.960 0.940 0.970 Appendix [25]c 
F4-DC to SVR (Genotype 3) 0.860 0.710 0.890 Appendix [25]c 
F0-F3 to SVR (Genotype 4 and more) 0.963 0.940 1.000 Appendix [25]c 
F4-DC to SVR (Genotype 4 and more) 0.943 0.800 0.970 Appendix [25]c 
Efficacy of treatments - 2017 Base-case Min Max Source 
F0-F3 to SVR (Genotype 1) 0.980 0.784 1.000 Appendix [25]c 
F4-DC to SVR (Genotype 1) 0.931 0.745 1.000 Appendix [25]c 
F0-F3 to SVR (Genotype 2) 0.980 0.784 1.000 Appendix [25]c 
F4-DC to SVR (Genotype 2) 0.970 0.776 1.000 Appendix [25]c 
F0-F3 to SVR (Genotype 3) 0.950 0.760 1.000 Appendix [25]c 
F4-DC to SVR (Genotype 3) 0.884 0.707 1.000 Appendix [25]c 
F0-F3 to SVR (Genotype 4 and more) 0.970 0.776 1.000 Appendix [25]c 
F4-DC to SVR (Genotype 4 and more) 0.961 0.769 1.000 Appendix [25]c 
Cost of treatment Base-case Min c Max c Source 
Treatment 2015 € 25,000.00 € 20,000 € 29,000 Assumption from [19] 
Treatment 2016 € 15,000.00 € 12,000 € 17,400 Assumption from [19] 
Treatment 2017 € 9,000.00 € 7,200 € 10,440 Assumption from [19] 
Other direct medical costs Base-case Min Max Source 
F0 € 222 € 176 € 292 [24, 25] 
F1 € 241 € 176 € 292 [24, 25] 
F2 € 215 € 176 € 292 [24, 25] 
F3 € 604 € 292 € 942 [24, 25] 
F4 € 904 € 397 € 1,354 [24, 25] 
Decompensated Cirrhosis (DC) € 5,961 € 4,385 € 8,868 [24, 25] 
HCC € 13,336 € 5,792 € 20,000 [24, 25] 
Transplant (procedure) € 76,036 € 62,648 € 84,900 [24, 25] 
Transplant (following years) € 1,870 € 0 € 4,729 [24, 25] 
SVR € 0 € 0 € 0 [24, 25] 
SVR to ILD states b € 2,186 € 397 € 2,483 Assumption from [23] 
a - Only for SVR to ILD 
b - Weighted average of states F4, DC and HCC (HCC costs are assumed equal to those of DC) 
c - Source [25] reports the rates of SVR obtained using an evidence-based review of information on the DAA regimen 
classified as “Recommended” or “Alternative” by the AASLD HCV guidelines [32] and the European Association for the Study of the 
Liver (EASL) [33] 
DC: decompensated cirrhosis; ILD: irreversible liver damage 
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3. Results 
 Of 5282 patients enrolled and evaluated for their access to DAA therapy (coming from 30 clinical centres 
distributed all over Italy), 2657 (51%) had consecutively undergone DAA therapy from January 2015 to December 
2017. Genotype (G) distribution analysis during this period showed that G1 represented the most frequent genotype in 
Italy in all 3 of the periods analysed (67% in 2015, 64% in 2016 and 62% in 2017), followed by G2 and G3. In 2015, 
over 60% of the treated patients were in the F4+ stage, while no more than 19% were in stages F0-F3 (Table 2). The 
distribution of treated patients in F0-F3 increased to 44% in 2016 and to 77% in 2017 (Table 2).  
Table 2 – Patient distribution by genotype, disease stage and year of starting treatment 
Genotype distribution in treated patients 2015 N 1390 (%) 
2016 
N 553 (%) 
2017 
N 665 (%) 
G1 938 (67%) 352 (64%) 415 (62%) 
G2 186 (13%) 100 (18%) 135 (20%) 
G3 154 (11%) 61 (11%) 65 (10%) 
G4 and Other 112 (8%) 40 (7%) 51 (8%) 
Fibrosis Year 2015 N 1340 (%) 
Year 2016 
N 553 (%) 
Year 2017 
N 665 (%) 
F0 72 (5%) 75 (14%) 192 (29%) 
F1 72 (5%) 75 (14%) 192 (29%) 
F2 131 (9%) 88 (16%) 127 (19%) 
F3 232 (17%) 115 (21%) 64 (10%) 
F4 722 (52%) 171 (31%) 77 (12%) 
DC 110 (8%) 19 (4%) 9 (1%) 
HCC 50 (4%) 10 (2%) 4 (1%) 
Total 100% 100% 100% 
  
Table 3 reports the clinical and economic results for a standardized population of 1,000 patients estimated by the model. 
The number of avoided HCV-related disease complications (DC, LT) was significantly higher in the first treatment 
period (2015) (980, 95% CI: 778-1221 avoided liver disease complications per 1,000) than in the subsequent years (722 
and 374 avoided liver disease complications in 2016 and 2017, respectively). Regarding costs, the potential clinical 
outcomes  reduction on  time estimated for patients treated in 2016 and 2017 reflect important cost savings over  20 
years period of time  (-€50.1, 95% CI: -21.4 to -79.3; and -€55.5, 95% CI: -30.4 to -85.5, respectively). For patients 
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treated in the year 2015, the liver disease complications avoided, , do not compensate the initial  investment in DAA . 
(€12.97 million increased costs, 95% CI: 3.4–42.5 million). 
 In the BPT analysis, the period of time required for the cumulative costs saved to recover the initial NHS 
investment in DAA treatment was estimated to be 6.6 years (95% CI: 5.4–9.1) for the 2016 treated patient cohort and 
6.2 years (95% CI: 5.3–7.6) for the 2017 cohort. This estimation means that the initial investment for drug acquisition 
by the Italian NHS will be compensated after 6.6 years for patients treated in 2016 and after 6.2 years for those treated 
in 2017. 
Table 3 – Base-case results and probabilistic sensitivity analysis  
Results BPT Avoided cases (BPT) 
Increasing costs after 
20 years 
(€ million) 
Avoided cases (after 20 
years) 
2015     €12.97 980 
(Min-Max)     (€ 2.35 - € 42.25) (778 - 1221) 
2016 6.6 377 - €50.12 722 
(Min-Max) (5.36 - 9.15) (328.25 - 470.91) (-€21.39 - -€ 79.26) (558 - 918) 
2017 6.2 145 - €55.50 374 
(Min-Max) (5.33 - 7.61) (129.33 - 170.98) (-€30.37 - -€85.49) (279 - 493) 
  
Figure 2 reports the break-even results in 2017 based on the DSA. The graph represents the variation in the time to 
recover the initial investment compared to the base-case results (line in the middle). The SVR rate of new DAAs 
represents the input parameter with the greatest impact on the BPT results (a lower level of SVR increased the BPT to 
7.2 years). Treatment costs, drug costs and transition probabilities had a moderate impact on the years needed for the 
return on investment (range 5.4–7.2), while transition probabilities and the distribution of the F3+ disease state had 
marginal impacts.  
 Considering the different models available in the literature on the disease progression of HCV patients, 
specific analyses were conducted on the BPT results using different transition probabilities. Figure 3 shows the BPT 
analysis for each cohort and the cost difference between the scenario with DAA treatment and the natural history of the 
disease. In all the analysed simulations, the distribution of the cost difference over time was consistent with the base-
case analysis (cost increase between €11 and €25 million at 20 years of follow-up; Figure 3.a). The uncertainty 
regarding the BPT and estimated cost reduction could make the return on investment become 6.5-9.2 years for patients 
treated in 2016 and 6.1–8.0 years for those treated in 2017 depending on the model used (Figure 3.b and Figure 3.c). 
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4. Discussion 
 The fibrosis stage distribution in the treated patients represents one of the main drivers for the return on 
investment from the Italian NHS perspective. Consistent with other studies published in the Italian context [12, 16], our 
work demonstrates that access to HCV treatment in earlier fibrosis stages of liver disease, which correspond to no or 
minimal liver damage, correlates with better outcomes from a clinical perspective and cost reduction over time.  
 In the pre-DAA era, Marcellusi et al. (2015) [24] estimated a total burden of disease between 0.61 and 1.63 
billion euros per year, of which 60.6% was associated with indirect costs (productivity loss) and 39.4% was associated 
with direct medical costs. No economic burden data are available regarding the post-DAA era. To our knowledge, this 
is the first study aiming to quantify the clinical and cost consequences of DAA investment and return from the NHS 
perspective. Moreover, this is the first cost-consequence analysis that is based on real-life data from a large sample of 
the Italian population for three different time periods. 
 Analysis of the clinical events potentially avoided over 20 years indicated a significant impact of the 
prioritized treatment (year 2015) on the reduction of severe clinical outcomes, such as progression of cirrhosis to DC, 
HCC and LT, and a less impact of DAA treatment on the reduction of these clinical events estimated by the model in 
patients treated in 2016 and 2017 Liver fibrosis is generally a slowly progressive disease characterized first by 
persistent hepatic inflammation, which could lead to the development of cirrhosis and HCC in the final stages of the 
disease progression. However, fibrosis progression is not linear, and its rates are extremely variable and can be 
influenced by host, viral and environmental factors [34-36]. Published data regarding the progression rates during HCV 
chronic infection are variable; progression rates to cirrhosis are as low as 2–3% to as high as 51% over 22 years [37, 
38]. Once cirrhosis is established, a high risk of HCC or hepatic decompensation (variceal haemorrhage, ascites, 
encephalopathy) and, following an episode of decompensation, a high risk of death have been reported [27, 39, 40].  For 
this reason, the clinical effect of treatment across this time period was obviously visible in patients treated in the first 
period (2015), as these patients mainly had advanced liver fibrosis with fast liver disease progression without an 
effective treatment. On the other hand, the clinical effect of treatment was less visible in the other two periods (2016 
and 2017) because the treated patients were mainly in the fibrosis stage F0-F3, therefore the severe liver disease 
outcomes would only appear in some of them in  20 years, even  without treatment .  
From the economic prespective, the nonprogression of liver disease following treatment in patients with liver fibrosis 
stages lower than F3, will consecutively have a cost reduction in their management over time. This explains the 
tendency of the relationship between the lower number of severe clinical outcomes avoided  and the higher amount of 
costs saved as well as the BPT for patients treated in 2016 and 2017. In contrast, treating prioritized patients in 2015 led 
to a greater estimated reduction in severe clinical outcomes but a lower cost savings  because the main management 
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costs persists regardless of virus eradication in patients with severe liver disease stage. This result, in combination with 
the higher drug costs in the first period, explain the not achievement of the  BPT for patients treated in 2015. 
Considering instead the final two periods, the difference in the severe clinical outcomes avoided was significantly 
higher for patients treated in 2016 due to the higher proportion of patients with fibrosis stages higher than F3 compared 
to those treated in 2017 (377% vs 145%).. However, this result does not translate to a significantly different amount of 
time required to recover the investment in DAA therapy because the DBT is related to two factors, drug cost and liver 
disease progression cost. Specifically, the cost of drugs administered to patients in 2016 was higher than that 
administered to patients in 2017, and the liver disease progression costs were also modelled to be higher due to the 
higher proportion of patients with a fibrosis stage >F3 in 2016 than in 2017 (37% vs 14%). These differences in both 
components of costs from which the DBT was derived explains the similar times required to reach the break-even 
points in both periods despite the different drug and disease costs in each of the periods analysed. 
 Moreover, as observed in the sensitivity analysis, considering different disease progressions compared to the 
base case, a lack of a BPT within the 20-year period cannot be ruled out. In fact, fibrosis progression in chronic HCV 
infection is not a linear process; it depends on several host factors, such as alcohol use, coinfection patterns, and 
metabolic disorders. Consequently, for a fibrosis stage higher than F3, different progression probabilities should be 
considered for economic evaluations. Considering the different progression probabilities available in the literature [4, 
23, 26] and the results reported in Figure 3.a and in Table 3, the return on investment in monetary terms could also 
never be fulfilled for patients treated in the severe liver disease stage, but a great return in terms of severe clinical 
outcmes avoided is observable.  
 Real-life clinical data suggest that following viral eradication due to DAA treatment, in the cirrhosis stage, 
some patients have significantly improved liver function tests, though some could still deteriorate, and HCC 
surveillance needs to continue despite virus elimination [31]. In several studies, improved liver function and reduction 
of LT necessity following HCV eradication after DAA treatment have been reported [31, 41-43]. On the other hand, 
treatment of patients with mild or no liver disease does not carry additive costs of management. In fact, comparing the 
third period (year 2017), in which a higher proportion of patients were treated in the F0-F2 fibrosis stage, to the first and 
second treatment periods (prioritized treatment), the reduction of liver-related events was lower in the third period, but 
the avoided costs were proportionally significantly higher. The real-life data clearly indicate the drastic reduction of 
costs for these latter patients compared to that for the others (PITER data not shown). In 2016, Linthicum et al. [26] 
investigated the value of expanding screening and treatment for HCV infection in the United States using the net social 
value of varying levels of access to treatment after diagnosis. This study demonstrated that such a “test-and-treat” 
strategy is likely to entail higher short-term costs but also yield the greatest social benefits. 
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 As is common in this type of analysis, different limitations exist related to the assumptions and adaptations 
needed to model the disease progression. First, this is a baseline analysis based on real-life data from treated patients, 
and several inputs in the model (disease progression, drug costs, drug efficacy in 2017) are based on literature data. This 
mixture of data is not perfectly coherent methodologically but considers all the available evidence and represents a 
proxy of what decision makers could expect from their public health decisions. Moreover, for the disease progression 
probabilities, no data are available for the specific Italian population chronically infected with HCV, but the use of 
different disease progressions reported in the literature in the DSA seems to limit this potential assumption bias. 
Second, antiviral treatment is considered effective if an SVR is reached at 12 weeks, which is a surrogate outcome. In 
fact, the outcome after SVR depends primarily on the fibrosis stage at treatment onset as well as on host-related and 
concomitant risk factors. Following HCV eradication after IFN-based treatment in noncirrhotic patients and patients 
without liver damage cofactors, no fibrosis progression or fibrosis regression has been reported [44, 45]. Regarding 
HCV eradication due to DAA use, no data are available to confirm this hypothesis, as HCV DAAs have been utilized 
for only a short time. However, real-life short-term DAA efficacy (SVR12) data from the PITER cohort confirm the 
assumption made in this model regarding patients with fibrosis in stages F0-F3 and partially confirm the assumption 
made for patients with a fibrosis stage higher than F3 [31]. A potential bias in not considering possible liver disease 
progression in patients with fibrosis at stages F0-F3 regardless of whether the virus is eradicated due to other liver 
disease cofactors should be considered in terms of the costs of liver disease in these patients and in future analyses. The 
uncertainties on the input were considered in the sensitivity analysis, and no significant variations were estimated. The 
lowest range of each parameter did not differ significantly from the result obtained in the base case, and moreover, very 
narrow differences in the BPT were estimated. Thirdly, DAA treatment costs were assumed to decrease over time to 
€10,000 and €6,000 in the first and second years of commercialization in Italy, respectively. This decrease represents 
the main driver in the BPT analysis, but no official references are available in Italy regarding the real DAA costs during 
this period (prices were covered by an agreement between the AIFA and pharmaceutical companies). However, based 
on nonofficial communications with the AIFA, these assumptions reflect, to a good approximation, the real-life costs 
paid by the Italian NHS for each DAA treatment per patient. Considering the lack of real-life medium- and long-term 
data on DAA effectiveness for patients with different profiles of chronic HCV liver disease and the overall morbidity 
stage, this analysis could help decision makers, as it reflects the real-life epidemiological and clinical patterns of treated 
patients in relation to overall patients in care.  
Finally, the model considered health effects and cost reductions for patients treated from 2015-2017. No assumptions 
were made for indirect effects on the general population (such as avoiding infections and eradication), and indirect costs 
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were not considered in the analysis. Therefore, the results might represent an underestimation of the actual health 
effects and avoided costs. 
5. Conclusion 
 The results of this cost-consequence analysis, which was based on real-life HCV treatment data from a 
representative sample of Italian patients in care, confirm an overall health benefit of treatment. This benefit is inversely 
correlated with cost savings in patients with severe liver disease over a 20-year evaluation period. The break-even point 
in time analysis demonstrated that following the emergency treatment of patients with severe liver disease, in whom 
only a health benefit was estimated, the current investment in universal DAA treatment is broadly cost saving. It is 
plausible to assume that the increasing trend in the Italian NHS return on investment estimated in this study will 
continue in the future, entailing lower investments and faster returns. This study may be a useful tool for public decision 
makers to understand how HCV epidemiological profiles influence the economic burden of HCV. 
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Fig 1 – State transition Markov model 
Legend: F: fibrosis stage; SVR: sustained virologic response; HCV: hepatitis C virus; HCC: hepatocellular carcinoma. 
 
Fig 2 – Deterministic sensitivity analysis of the discounted break-even point in time (2017): tornado diagram 
Legend: F: fibrosis stage; SVR: sustained virologic response; DC: decompensated cirrhosis; HCC: hepatocellular 
carcinoma. 
 
Fig 3 – Deterministic sensitivity analysis: Markov cost tracking with the input transition probabilities of Razavi 2014 
[4], Cortesi 2015 [23] Lithicum 2016 [26] and base-case. 
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